When most people hear about GLP-1 medications such as semaglutide or tirzepatide, they immediately think about weight loss. But weight reduction is only part of the story. Research over the past several years has shown that medications affecting the GLP-1 pathway may...
If you’ve heard about Zepbound® (tirzepatide) and are wondering whether Medicare will help pay for it in 2026, you’re not alone. Millions of older Americans struggle with obesity and its complications, including heart disease, sleep apnea, arthritis, high...
Why Are GLP-1 Medications Helping So Many Different Medical Conditions? For years, GLP-1 medications such as semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®) were viewed primarily as weight-loss or diabetes medications. Today, researchers are...
The short answer is generally no. If you already receive coverage for a GLP-1 medication such as Ozempic® through your Medicare Part D prescription drug plan for Type 2 diabetes, you generally cannot switch to the Medicare GLP-1 Bridge Program. The Bridge Program was...
A Review of the Science Behind Medicare’s New Approach to Obesity Treatment and Cardiovascular Disease Prevention Beginning in July 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge Program, a temporary demonstration...
